ナノボディの世界市場

ナノボディの世界市場は2030年までに15億米ドルに到達

2024年に5億6,100万米ドルと推定されるナノボディの世界市場は、分析期間2024-2030年にCAGR 18.0％で成長し、2030年には15億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである単特異型は、CAGR 19.5%を記録し、分析期間終了時には11億米ドルに達すると予測されます。マルチスペシフィックタイプセグメントの成長率は、分析期間中CAGR 14.8％と推定されます。

米国市場は1億5,280万米ドルと推定、中国はCAGR24.0％で成長すると予測

米国のナノボディ市場は、2024年に1億5,280万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに3億4,240万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは24.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、それぞれ分析期間中に13.2%と16.4%のCAGRで成長すると予測されています。欧州では、ドイツがCAGR約14.4%で成長すると予測されています。

世界のナノボディ市場- 主要動向と促進要因のまとめ

ナノボディが治療薬や診断薬で勢いを増す理由とは？

シングルドメイン抗体としても知られるナノボディは、ラクダ科の動物に由来するユニークな抗体断片です。従来の抗体とは異なり、ナノボディは小さく安定で、隠れたエピトープや到達困難なエピトープに結合することができます。そのコンパクトなサイズは、組織への浸透性、血流からの迅速なクリアランス、製造の容易さを可能にします。これらの特性は、腫瘍学、自己免疫疾患、感染症治療、画像診断への応用に非常に魅力的です。

また、構造が単純であるため、多特異的フォーマットや融合タンパク質への迅速なエンジニアリングが可能です。ナノボディは、吸入や局所適用といった従来とは異なる経路で送達することができ、注射可能な生物製剤に代わる選択肢を提供します。製薬開発者は、標的を絞り、即効性があり、費用対効果の高い生物製剤をますます求めており、ナノボディは、治療開発とin vivo診断の両方において、次世代のツールとして位置づけられています。

デザインとデリバリーにおける革新は、ナノボディの可能性をどのように広げているのか？

タンパク質工学とファージディスプレイ・ライブラリーの進歩により、ナノボディの探索と親和性の最適化が向上しています。研究開発者は、ラクダ免疫に直接依存することなく合成ナノボディライブラリを作成できるようになり、開発期間が短縮されています。ナノボディは多価のフォーマットで設計されており、結合強度を高めたり、複数のターゲットに同時に作用したりします。

ドラッグデリバリーでは、ナノボディは毒素、サイトカイン、あるいは放射性核種と融合され、疾患細胞を選択的に標的とします。大腸菌や酵母のような微生物系で発現させることができるため、完全長のモノクローナル抗体と比較して生産コストが削減されます。ナノボディ-薬物複合体、ナノボディに基づくCAR-T療法、二重特異性フォーマットも活発に開発されています。これらの進歩により、全身への曝露や免疫関連の毒性を最小限に抑えながら、治療用ペイロードをオーダーメイドで送達することが可能になります。

研究および臨床の場で需要を牽引しているアプリケーションは？

診断学では、ナノボディはバイオセンサー、イムノアッセイ、分子イメージングツールに広く使用されています。過酷な条件下での安定性により、ポイントオブケア検査やフィールドベースの検出システムに適しています。イメージングでは、ナノボディベースのPETトレーサーは、従来の抗体と比較して、より高い解像度とより速いクリアランスで、腫瘍、炎症、感染部位をリアルタイムで可視化することを可能にします。

治療面では、炎症性疾患、がん、神経変性疾患、COVID-19を含むウイルス感染症に対する研究が進められています。腫瘍学では、ナノボディ-薬物複合体や免疫チェックポイント阻害剤が初期段階の臨床試験で有望視されています。神経学では、血液脳関門を通過するナノボディーの能力が、アルツハイマー病やパーキンソン病などの疾患におけるアミロイド斑やミスフォールディングタンパク質への標的送達のために評価されています。獣医学と農業バイオテクノロジーも、病気の制御と検出のためにナノボディを研究しています。

ナノボディ市場の成長はいくつかの要因によって牽引される...

ナノボディ市場の成長は、いくつかの要因によって牽引されています。標的生物製剤や精密診断に対する需要の高まりは、小型で親和性の高い結合分子の開発を促進します。合成生物学とディスプレイ技術の進歩がナノボディの発見とスクリーニングを加速します。費用対効果の高い微生物発現システムは、スケーラブルな生産をサポートします。生物製剤の臨床パイプラインと規制当局のサポートが拡大し、商業的実現性が高まる。腫瘍学、神経変性、感染症研究への投資が増加し、新たな応用機会が生まれます。バイオテクノロジー企業、学術研究所、製薬企業間のパートナーシップは、製品開発、ライセンシング、市場開拓をさらにサポートします。

セグメント

タイプ（単特異的タイプ、多特異的タイプ）、用途（後天性血栓性血小板減少性紫斑病用途、呼吸器合胞体ウイルス感染症用途、関節リウマチ用途、全身性エリテマトーデス用途、腫瘍用途、乾癬用途、骨疾患用途、その他用途）、最終用途（製薬企業・バイオテクノロジー企業最終用途、研究所最終用途、その他最終用途）

調査対象企業の例

• AbCellera Biologics Inc.
• Abiocenter
• Alpaca Nanobodies Inc.
• Amgen Inc.
• BIOCYTOGEN Group
• Bio-Rad Laboratories
• Boehringer Ingelheim GmbH
• Capralogics Inc.
• Creative Biolabs
• Cusabio
• GenScript Biotech Corporation
• Merck KGaA
• Morphosys AG（Ablynx tech）
• NanoTag Biotechnologies GmbH
• Novartis AG
• Proteintech Group, Inc.
• PREGENE
• QVQ Holding BV
• Sanofi（Ablynx）
• Thermo Fisher Scientific
• Yiteng Pharmaceutical

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Nanobodies Market to Reach US$1.5 Billion by 2030

The global market for Nanobodies estimated at US$561.0 Million in the year 2024, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 18.0% over the analysis period 2024-2030. Mono-Specific Type, one of the segments analyzed in the report, is expected to record a 19.5% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Multi-Specific Type segment is estimated at 14.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$152.8 Million While China is Forecast to Grow at 24.0% CAGR

The Nanobodies market in the U.S. is estimated at US$152.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$342.4 Million by the year 2030 trailing a CAGR of 24.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.2% and 16.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.4% CAGR.

Global Nanobodies Market - Key Trends & Drivers Summarized

Why Are Nanobodies Gaining Momentum in Therapeutics and Diagnostics?

Nanobodies, also known as single-domain antibodies, are a unique class of antibody fragments derived from camelid species. Unlike conventional antibodies, nanobodies are small, stable, and can bind to hidden or difficult-to-reach epitopes. Their compact size allows better tissue penetration, rapid clearance from the bloodstream, and ease of manufacturing. These properties make them highly attractive for applications in oncology, autoimmune diseases, infectious disease treatment, and diagnostic imaging.

Their structural simplicity also enables rapid engineering into multi-specific formats or fusion proteins. Nanobodies can be delivered through non-traditional routes such as inhalation or topical application, offering alternatives to injectable biologics. With pharmaceutical developers increasingly seeking targeted, fast-acting, and cost-effective biologics, nanobodies are positioned as next-generation tools in both therapeutic development and in vivo diagnostics.

How Is Innovation in Design and Delivery Expanding Nanobody Potential?

Advances in protein engineering and phage display libraries are improving nanobody discovery and affinity optimization. Researchers can now generate synthetic nanobody libraries without direct reliance on camelid immunization, accelerating development timelines. Nanobodies are being designed for multivalent formats, which enhance binding strength or engage multiple targets simultaneously-especially relevant in cancer immunotherapy and viral neutralization.

In drug delivery, nanobodies are being fused with toxins, cytokines, or radionuclides to selectively target diseased cells. Their ability to be expressed in microbial systems like E. coli or yeast reduces production costs compared to full-length monoclonal antibodies. Nanobody-drug conjugates, nanobody-based CAR-T therapies, and bispecific formats are also under active development. These advances allow tailored delivery of therapeutic payloads while minimizing systemic exposure and immune-related toxicity.

Which Applications Are Driving Demand Across Research and Clinical Settings?

In diagnostics, nanobodies are widely used in biosensors, immunoassays, and molecular imaging tools. Their stability under extreme conditions makes them suitable for point-of-care testing and field-based detection systems. In imaging, nanobody-based PET tracers enable real-time visualization of tumors, inflammation, or infectious sites with higher resolution and faster clearance compared to conventional antibodies.

Therapeutically, nanobodies are being investigated for inflammatory conditions, cancers, neurodegenerative diseases, and viral infections including COVID-19. In oncology, nanobody-drug conjugates and immune checkpoint inhibitors are showing promise in early-phase clinical trials. In neurology, their ability to cross the blood-brain barrier is under evaluation for targeted delivery to amyloid plaques or misfolded proteins in diseases like Alzheimer’s and Parkinson’s. Veterinary medicine and agricultural biotechnology are also exploring nanobodies for disease control and detection.

Growth in the Nanobodies Market Is Driven by Several Factors…

Growth in the nanobodies market is driven by several factors. Rising demand for targeted biologics and precision diagnostics encourages development of compact and high-affinity binding molecules. Advances in synthetic biology and display technologies accelerate nanobody discovery and screening. Cost-effective microbial expression systems support scalable production. Expanding clinical pipeline and regulatory support for biologics enhance commercial viability. Increased investment in oncology, neurodegeneration, and infectious disease research creates new application opportunities. Partnerships between biotech firms, academic labs, and pharmaceutical companies further support product development, licensing, and market expansion.

SCOPE OF STUDY:

The report analyzes the Nanobodies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Mono-Specific Type, Multi-Specific Type); Application (Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application, Bone Disorders Application, Other Applications); End-Use (Pharma & Biotech Companies End-Use, Research Laboratories End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• AbCellera Biologics Inc.
• Abiocenter
• Alpaca Nanobodies Inc.
• Amgen Inc.
• BIOCYTOGEN Group
• Bio-Rad Laboratories
• Boehringer Ingelheim GmbH
• Capralogics Inc.
• Creative Biolabs
• Cusabio
• GenScript Biotech Corporation
• Merck KGaA
• Morphosys AG (Ablynx tech)
• NanoTag Biotechnologies GmbH
• Novartis AG
• Proteintech Group, Inc.
• PREGENE
• QVQ Holding BV
• Sanofi (Ablynx)
• Thermo Fisher Scientific
• Yiteng Pharmaceutical

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Nanobodies - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Demand for Targeted and Versatile Biotherapeutics Drives Interest in Nanobody-Based Drug Development
  • Superior Stability and Smaller Molecular Size of Nanobodies Throws Spotlight on Their Use in Hard-to-Reach Targets
  • Advancements in Immunotherapy and Oncology Research Propel Adoption of Nanobody-Based Modalities
  • Expansion of Bispecific and Multivalent Therapeutics Supports Use of Nanobodies in Complex Drug Design
  • Growing Research Activity in Autoimmune and Inflammatory Diseases Enhances Scope for Nanobody Applications
  • Increased Use of Nanobodies in Diagnostic Imaging and Molecular Tracers Strengthens Demand in Precision Medicine
  • OEM Collaborations With Academic Institutions Accelerate Innovation in Rare and Orphan Disease Therapeutics
  • Favorable Pharmacokinetics and Reduced Immunogenicity Drive Preference Over Conventional Antibodies
  • Emerging Interest in Inhalable and Topical Drug Delivery Formats Fuels Development of Nanobody-Based Treatments
  • Growth in CNS and Blood-Brain Barrier Research Encourages Nanobody Use for Neurological Conditions
  • Vaccine Development and Viral Neutralization Studies Highlight Role of Nanobodies in Infectious Disease Management
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Nanobodies Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Nanobodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Nanobodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Nanobodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Mono-Specific Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Mono-Specific Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Mono-Specific Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Multi-Specific Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Multi-Specific Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Multi-Specific Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Acquired Thrombotic Thrombocytopenic Purpura Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Acquired Thrombotic Thrombocytopenic Purpura Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Acquired Thrombotic Thrombocytopenic Purpura Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Respiratory Syncytial Virus Infection Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Respiratory Syncytial Virus Infection Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Respiratory Syncytial Virus Infection Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Rheumatoid Arthritis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Rheumatoid Arthritis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Systemic Lupus Erythematosus Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Systemic Lupus Erythematosus Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Systemic Lupus Erythematosus Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Psoriasis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Psoriasis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Psoriasis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Bone Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Bone Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Bone Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Research Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Research Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Research Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 44: USA Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: USA 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: USA 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: Canada 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: Canada 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• JAPAN
  • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: Japan 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: Japan 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: Japan 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• CHINA
  • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 71: China Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: China 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: China 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: China 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• EUROPE
  • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Nanobodies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Nanobodies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Nanobodies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: Europe 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: Europe 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: Europe 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• FRANCE
  • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 92: France Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: France 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: France 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 98: France Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: France 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• GERMANY
  • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: Germany 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 106: Germany 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 109: Germany 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 112: Italy 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 115: Italy 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 118: Italy 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 119: UK Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 121: UK 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 124: UK 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 125: UK Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 127: UK 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 130: Spain 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 133: Spain 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 136: Spain 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 139: Russia 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 142: Russia 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 145: Russia 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Nanobodies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Nanobodies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Nanobodies by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 169: Australia 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 172: Australia 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 175: Australia 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• INDIA
  • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 176: India Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 178: India 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 181: India 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 182: India Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 184: India 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 187: South Korea 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 190: South Korea 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 193: South Korea 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Nanobodies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Nanobodies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Nanobodies by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 208: Latin America 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 211: Latin America 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 214: Latin America 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 217: Argentina 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 220: Argentina 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 223: Argentina 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 226: Brazil 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 229: Brazil 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 232: Brazil 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 235: Mexico 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 238: Mexico 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 241: Mexico 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Nanobodies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Nanobodies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Nanobodies by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 256: Middle East 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 259: Middle East 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 262: Middle East 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 265: Iran 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 268: Iran 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 271: Iran 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 274: Israel 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 277: Israel 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 280: Israel 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 292: UAE 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 295: UAE 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 298: UAE 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• AFRICA
  • Nanobodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Nanobodies by Type - Mono-Specific Type and Multi-Specific Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 310: Africa 16-Year Perspective for Nanobodies by Type - Percentage Breakdown of Value Sales for Mono-Specific Type and Multi-Specific Type for the Years 2014, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Nanobodies by Application - Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 313: Africa 16-Year Perspective for Nanobodies by Application - Percentage Breakdown of Value Sales for Other Applications, Acquired Thrombotic Thrombocytopenic Purpura Application, Respiratory Syncytial Virus Infection Application, Rheumatoid Arthritis Application, Systemic Lupus Erythematosus Application, Oncology Application, Psoriasis Application and Bone Disorders Application for the Years 2014, 2025 & 2030
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Nanobodies by End-Use - Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 316: Africa 16-Year Perspective for Nanobodies by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Laboratories End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION